BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 25402979)

  • 1. Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention.
    Shen C; Vakoc CR
    Curr Opin Oncol; 2015 Jan; 27(1):57-63. PubMed ID: 25402979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer.
    Plass C; Pfister SM; Lindroth AM; Bogatyrova O; Claus R; Lichter P
    Nat Rev Genet; 2013 Nov; 14(11):765-80. PubMed ID: 24105274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.
    Popovic R; Martinez-Garcia E; Giannopoulou EG; Zhang Q; Zhang Q; Ezponda T; Shah MY; Zheng Y; Will CM; Small EC; Hua Y; Bulic M; Jiang Y; Carrara M; Calogero RA; Kath WL; Kelleher NL; Wang JP; Elemento O; Licht JD
    PLoS Genet; 2014 Sep; 10(9):e1004566. PubMed ID: 25188243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depletion of H3K36me2 recapitulates epigenomic and phenotypic changes induced by the H3.3K36M oncohistone mutation.
    Rajagopalan KN; Chen X; Weinberg DN; Chen H; Majewski J; Allis CD; Lu C
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone H2A ubiquitination inhibits the enzymatic activity of H3 lysine 36 methyltransferases.
    Yuan G; Ma B; Yuan W; Zhang Z; Chen P; Ding X; Feng L; Shen X; Chen S; Li G; Zhu B
    J Biol Chem; 2013 Oct; 288(43):30832-42. PubMed ID: 24019522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo?
    Chan KM; Han J; Fang D; Gan H; Zhang Z
    Cell Cycle; 2013 Aug; 12(16):2546-52. PubMed ID: 23907119
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
    Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The trithorax group proteins Kismet and ASH1 promote H3K36 dimethylation to counteract Polycomb group repression in Drosophila.
    Dorighi KM; Tamkun JW
    Development; 2013 Oct; 140(20):4182-92. PubMed ID: 24004944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation.
    Hacker KE; Fahey CC; Shinsky SA; Chiang YJ; DiFiore JV; Jha DK; Vo AH; Shavit JA; Davis IJ; Strahl BD; Rathmell WK
    J Biol Chem; 2016 Sep; 291(40):21283-21295. PubMed ID: 27528607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin.
    Sankaran SM; Wilkinson AW; Elias JE; Gozani O
    J Biol Chem; 2016 Apr; 291(16):8465-74. PubMed ID: 26912663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic cross-talk between DNA methylation and histone modifications in human cancers.
    Kondo Y
    Yonsei Med J; 2009 Aug; 50(4):455-63. PubMed ID: 19718392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probe the function of histone lysine 36 methylation using histone H3 lysine 36 to methionine mutant transgene in mammalian cells.
    Fang D; Gan H; Wang H; Zhou H; Zhang Z
    Cell Cycle; 2017 Oct; 16(19):1781-1789. PubMed ID: 28129023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
    Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
    J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
    Morishita M; Mevius D; di Luccio E
    BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative proteomics reveals that the specific methyltransferases Txr1p and Ezl2p differentially affect the mono-, di- and trimethylation states of histone H3 lysine 27 (H3K27).
    Zhang C; Molascon AJ; Gao S; Liu Y; Andrews PC
    Mol Cell Proteomics; 2013 Jun; 12(6):1678-88. PubMed ID: 23150054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis of the regulation of the normal and oncogenic methylation of nucleosomal histone H3 Lys36 by NSD2.
    Sato K; Kumar A; Hamada K; Okada C; Oguni A; Machiyama A; Sakuraba S; Nishizawa T; Nureki O; Kono H; Ogata K; Sengoku T
    Nat Commun; 2021 Nov; 12(1):6605. PubMed ID: 34782608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas.
    Fang D; Gan H; Lee JH; Han J; Wang Z; Riester SM; Jin L; Chen J; Zhou H; Wang J; Zhang H; Yang N; Bradley EW; Ho TH; Rubin BP; Bridge JA; Thibodeau SN; Ordog T; Chen Y; van Wijnen AJ; Oliveira AM; Xu RM; Westendorf JJ; Zhang Z
    Science; 2016 Jun; 352(6291):1344-8. PubMed ID: 27229140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of chromatin: status and opportunities.
    Siklos M; Kubicek S
    FEBS J; 2022 Mar; 289(5):1276-1301. PubMed ID: 33982887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-driving H3G34V/R/D mutations block H3K36 methylation and H3K36me3-MutSα interaction.
    Fang J; Huang Y; Mao G; Yang S; Rennert G; Gu L; Li H; Li GM
    Proc Natl Acad Sci U S A; 2018 Sep; 115(38):9598-9603. PubMed ID: 30181289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
    Xu B; Konze KD; Jin J; Wang GG
    Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.